Spinal fusion material, BMP, increases risk of benign tumors, not cancer

September 6, 2013
Spinal fusion material, BMP, increases risk of benign tumors, not cancer

Using a certain bone grafting material for spinal fusion, one of the most common procedures for people with painful vertebral deteriorations, does not appear to result in higher rates of cancer, according to researchers at Duke Medicine.

However, the researchers found that the bone promoter known as recombinant human 2, or BMP, is associated with a higher rate of in the brain and nervous system.

Reported in the September 2013, print edition of the journal Neurosurgery, the finding provides a better understanding of the long-term outcomes of spinal fusions using BMP. Recent studies have suggested that the is associated with harmful effects, including increased rates of cancer when used in high doses, leading to a decision by the U.S. Food and Drug Administration to reject approval of the higher dosage formulation.

Although BMP is approved only for use in the lower spine with anterior approaches for surgery, it has been widely used "off-label" in cervical fusions, posterior lumbar procedures, and minimally invasive approaches.

"Given the widespread use of BMP, there has been a tremendous need for better data about its effects," said lead author Nandan Lad, M.D., Ph.D., assistant professor in the division of neurosurgery at Duke University School of Medicine. "Our study is the largest to date examining the association between BMP use and cancer."

Using national claims data from commercial insurers, Medicaid and Medicare, Lad and colleagues conducted a large, of more than 4,600 patients who had undergone spinal fusions with BMP and matched them against similar patients who had the procedure without the material. They examined the association between BMP and the general risk of cancer, as well as the risk of developing cancer in different tissues.

Overall, the Duke-led team found that 9.4 percent of patients receiving BMP developed malignant cancers, compared to 8.4 percent of patients not receiving the growth factor – a difference that was not statistically significant.

For benign tumors, there was a significantly higher risk. After adjusting to better match patients in both groups to eliminate selection bias, the researchers found that those who received BMP were 31 percent more likely to be diagnosed with benign tumors than those who did not receive the graft material. These tumors included non-malignant growths in the brain and nervous system.

"While the absolute risks were small overall, the increased risk for soft tissue tumors and those lining the nervous system among patients receiving BMP may be caused by the large local dose of BMP that is administered to the spine, and warrants further study," Lad said.

Lad said findings should be viewed with caution, noting that the limitations of the study include its retrospective design. However, the ethical and practical complications of prospectively enlisting patients in a head-to-head comparison of BMP against no growth factor made a large, retrospective study the next-best approach. Lad said the study also relies on accurate and timely diagnoses of cancer and benign tumors among the study population.

"We believe this study is the first to specifically investigate the association between the use of BMP and risk in a systematic manner, and apply it to the general population of undergoing spinal fusion in the United States," Lad said.

Explore further: Bone growth factor may increase benign tumors but not malignant cancer

Related Stories

Bone growth factor may increase benign tumors but not malignant cancer

September 6, 2013
Patients undergoing spinal fusion surgery with bone morphogenetic protein (BMP) appear to be at increased risk of benign tumors—but not cancers, reports a study in the September issue of Neurosurgery, official journal of ...

Neurosurgery publishes findings of three important studies in June issue

June 19, 2013
The results of three important studies have been published in the June issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

Study finds increased cancer risk with bone growth product

November 4, 2011
Spine surgery patients who got a bone growth stimulating agent as part of a clinical trial were three to five times more likely to develop cancer two to three years after being implanted with the product, according to a new ...

Racial disparities exist in outcomes of spinal surgery

June 18, 2013
(HealthDay)—The rate of complications, length of stay, and costs associated with surgery for lumbar spinal stenosis differ for African-American patients compared with white patients, according to research published in the ...

Recommended for you

World's first child hand transplant a 'success'

July 19, 2017
The first child in the world to undergo a double hand transplant is now able to write, feed and dress himself, doctors said Tuesday, declaring the ground-breaking operation a success after 18 months.

Knee surgery—have we been doing it wrong?

July 18, 2017
A team of University at Buffalo medical doctors have published a study that challenges a surgical practice used for decades during arthroscopic knee surgery.

New tools help surgeons find liver tumors, not nick blood vessels

July 17, 2017
The liver is a particularly squishy, slippery organ, prone to shifting both deadly tumors and life-preserving blood vessels by inches between the time they're discovered on a CT scan and when the patient is lying on an operating ...

Researchers discover indicator of lung transplant rejection

July 13, 2017
Research by scientists at Dignity Health St. Joseph's Hospital and Medical Center's Norton Thoracic Institute was published in the July 12, 2017 issue of Science Translational Medicine titled "Zbtb7a induction in alveolar ...

New device could make closing surgical incisions a cinch

July 7, 2017
Like many surgeons, Dr. Jason Spector is often faced with the challenge of securely closing the abdominal wall without injuring the intestines. If the process goes awry, there can be serious consequences for patients, including ...

Success with first 20 patients undergoing minimally invasive pancreatic transplant surgery

June 29, 2017
Surgeons at Johns Hopkins Medicine report that their first series of a minimally invasive procedure to treat chronic pancreas disease, known as severe pancreatitis, resulted in shorter hospital stays, less need for opioids ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.